Journey Medical (DERM) Common Equity (2020 - 2026)

Journey Medical's Common Equity history runs 7 years deep, the most recent figure standing at $30.8 million for Q1 2026.

• Quarterly Common Equity rose 43.13% year-over-year to $30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.8 million (up 43.13% YoY) and the FY2025 annual result came in at $31.9 million, up 58.71% from the prior year.
• Common Equity was $30.8 million for Q1 2026 at Journey Medical, down from $31.9 million in the prior quarter.
• Across five years, Common Equity topped out at $41.4 million in Q1 2022 and bottomed at $5000.0 in Q2 2023.
• A 5-year average of $20.5 million and a median of $20.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity sank 99.99% — and 2024, when it soared 225800.0%.
• Journey Medical's Common Equity stood at $17.0 million in 2022, then advanced by 19.83% to $20.3 million in 2023, then decreased by 1.38% to $20.1 million in 2024, then surged by 58.71% to $31.9 million in 2025, then decreased by 3.21% to $30.8 million in 2026.
• Business Quant data shows DERM's Common Equity at $30.8 million in Q1 2026, $31.9 million in Q4 2025, and $25.9 million in Q3 2025.